Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × GIST × Clear all

Phase

Phase 2 2 Phase NA 1 Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 936 Carcinoma, Non-Small-Cell Lung 585 Neoplasms 460 Prostatic Neoplasms 420 Colorectal Neoplasms 357 Multiple Myeloma 283 Neoplasm Metastasis 252 Lung Neoplasms 251 Leukemia, Myeloid, Acute 224 Stomach Neoplasms 214 Carcinoma, Hepatocellular 214 Ovarian Neoplasms 185 Rectal Neoplasms 178 Lymphoma, Follicular 170 Colonic Neoplasms 167 Lymphoma 166 Leukemia 153 Pancreatic Neoplasms 148 Uterine Cervical Neoplasms 146 Lymphoma, Non-Hodgkin 144 Head and Neck Neoplasms 142 Recurrence 136 Lymphoma, Large B-Cell, Diffuse 136 Precursor Cell Lymphoblastic Leukemia-Lymphoma 134 Leukemia, Lymphocytic, Chronic, B-Cell 133 Melanoma 131 Brain Neoplasms 121 Urinary Bladder Neoplasms 119 Squamous Cell Carcinoma of Head and Neck 117 Pain 114

Interventions

olverembatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06640361 2024-12-27

A Study of Olverembatinib in SDH-deficient GIST.

Ascentage Pharma Group Inc.

Phase 3 Recruiting

GIST

Data powered by HemOnc (CC BY 4.0) Colophon ⚡